Trial met its primary endpoint, with each dose group showing rapid improvement in Positive and Negative Syndrome Scale (PANSS) total score and achieving statistically significant and clinically meaningful improvement versus placebo at Day 42 (p<0.0001)

Accomplished Biopharma Executive Joins Tortugas to Help Lead Continued Growth

“Jim’s wealth of experience in CNS drug development, coupled with his deep financial acumen, will be invaluable to our company and clinical-development strategies,” said Jeff Jonas, M.D., Chief Executive Officer of Tortugas.

Biotech Veterans Jeff Jonas and Al Robichaud to Lead Company with Investment from Cure Ventures, The Column Group, and AN Ventures